Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
-
Biomed. Pharmacother. · Jan 2021
Randomized Controlled Trial Multicenter StudyTocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19. ⋯ Tocilizumab combined with or without favipiravir can effectively improve the pulmonary inflammation of COVID-19 patients and inhibit the deterioration of the disease.